Comparative Pharmacology
Head-to-head clinical analysis: A POXIDE versus DIAZEPAM INTENSOL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: A POXIDE versus DIAZEPAM INTENSOL.
A-POXIDE vs DIAZEPAM INTENSOL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
GABA-A receptor positive allosteric modulator; increases chloride ion influx and neuronal hyperpolarization.
Benzodiazepine that potentiates GABA-A receptor activity by binding to the benzodiazepine site, increasing chloride ion conductance and neuronal inhibition.
GERD: 20 mg orally once daily for 4-8 weeks. Erosive esophagitis: 40 mg once daily for 8 weeks. H. pylori eradication: 20 mg twice daily with amoxicillin and clarithromycin for 14 days.
2 to 10 mg orally 2 to 4 times daily, as needed for anxiety or muscle spasm; 10 mg orally before procedures for sedation. Maximum 40 mg/day.
None Documented
None Documented
Terminal elimination half-life is 12-18 hours (mean 15 hours) in adults with normal renal function. Prolonged to 24-36 hours in elderly or moderate renal impairment (CrCl < 50 mL/min).
Terminal elimination half-life is 20–50 hours (mean ~30 hours) in adults, with significant interindividual variability; prolonged in elderly, hepatic impairment, and neonates (up to 100 hours).
Renal excretion accounts for 60-70% of elimination, predominantly as unchanged drug. Biliary/fecal excretion accounts for 20-30%, with approximately 10% eliminated in feces as metabolites.
Renal excretion of metabolites (primarily glucuronide conjugates) accounts for ~70% of elimination; fecal excretion accounts for ~10%; unchanged drug in urine is <1%.
Category C
Category D/X
Benzodiazepine
Benzodiazepine